|Bid||2.4700 x 1000|
|Ask||3.3400 x 1000|
|Day's range||3.3000 - 3.3200|
|52-week range||1.8000 - 5.9600|
|Beta (5Y monthly)||4.77|
|PE ratio (TTM)||N/A|
|Earnings date||14 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.00|
Upon this stockholder approval, on May 15, 2020, the Company completed the $8 million convertible preferred stock financing by investment funds affiliated with Park West Asset Management LLC and MSD Partners, L.P. Please refer to the Company’s Form 8-K, filed with the U.S. Securities and Exchange Commission on March 13, 2020, for a description of the terms of the convertible preferred stock transaction.
-- Company to begin bioequivalence study of VAZALORE 325 mg dose ---- sNDA submissions expected by year-end -- SPARTA, N.J., May 15, 2020 -- PLx Pharma Inc. (NASDAQ: PLXP).
SPARTA, N.J., May 04, 2020 -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically.